Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib [0.03%]
I型神经纤维瘤病的治疗进展：注重考比替尼的应用
Faith Cormier,Irene Lara-Corrales,Maxwell Sauder et al.
Faith Cormier et al.
Neurofibromatosis type 1 (NF1) is a genetic condition inherited in an autosomal dominant pattern, but with 50% of cases caused by de novo mutations. Neurofibromin, the gene product in NF1, regulates the RAS/MAPK pathway, and mutation can le...
Review
Skin therapy letter. 2025 Sep;30(5):1-4. DOI: 2025
Nanodermatology [0.03%]
纳米皮肤病学
Claire Fason,Stephen K Tyring
Claire Fason
Nanodermatology has been an emerging area of research and drug development in the last two decades. Nanodermatology lies at the intersection of nanotechnology, chemical engineering, biophysics, and pharmacology. Increasing research has yiel...
Review
Skin therapy letter. 2025 Jul;30(4):8-11. DOI: 2025
Leah Johnston,Susan Poelman,Andrei Metelitsa
Leah Johnston
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that impacts approximately 10-15% of the population in the United States and Canada. Lebrikizumab is a novel systemic human monoclonal immunoglobulin G4 antibody that ...
Review
Skin therapy letter. 2025 Jul;30(4):1-7. DOI: 2025
A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne [0.03%]
用于中重度痤疮的新型复方固定剂量三联疗法(IDP-126)
Karen Michael,Jaefer Mohamad,Nuha Nasir et al.
Karen Michael et al.
Clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126) is a novel fixed-dose triad gel combination approved by the US FDA October 2023 and by Health Canada August 2024 for the treatment of acne vulgaris in patients aged ...
Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis [0.03%]
Nemolizumab治疗扁平湿疣和特应性皮炎的使用
Mohamad R Taha,Stephen K Tyring
Mohamad R Taha
Prurigo nodularis and atopic dermatitis are chronic, inflammatory skin conditions characterized by significant pruritus that disrupts daily life. They also involve dysfunction of the T-helper 2 immune response, leading to the over secretion...
Review
Skin therapy letter. 2025 May;30(3):1-3. DOI: 2025
Targeting IL-23 in Psoriatic Arthritis: A Review of Guselkumab's Efficacy and Utilization [0.03%]
IL-23在银屑病关节炎中的靶向治疗：Guselkumab的疗效和应用综述
Alisha Kashyap,Kevin M Burningham,Stephen K Tyring
Alisha Kashyap
Psoriatic arthritis (PsA) is a chronic, inflammatory disease with heterogeneous clinical features. The pathogenesis of PsA involves a complex interplay of genetic, immunologic, and environmental factors, leading to the activation of the imm...
Review
Skin therapy letter. 2025 Mar;30(2):5-7. DOI: 2025
Austinn C Miller,Abigail E Watson,Marc J Inglese
Austinn C Miller
Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of M...
Review
Skin therapy letter. 2025 Mar;30(2):1-4. DOI: 2025
Zeyad Koussayer,Judy Koussayer,Stephen K Tyring
Zeyad Koussayer
Cutaneous leishmaniasis (CL) is an infection caused by the Leishmania protozoa, which are primarily transmitted through bites of infected female sandflies. This article provides a comprehensive overview of the clinical management of CL, inc...
Review
Skin therapy letter. 2025 Jan;30(1):5-9. DOI: 2025
Jordanna Roesler,Allison Gregory,Wingfield Rehmus
Jordanna Roesler
Hidradenitis suppurativa (HS) is a chronic, recurring inflammatory skin disease that significantly impacts the quality of life of patients.[1] HS is more common in adults and adolescents, although true incidence rates may be underestimated ...
Review
Skin therapy letter. 2025 Jan;30(1):1-4. DOI: 2025
Mohamad R Taha,Stephen K Tyring
Mohamad R Taha
A biofilm is a diverse community of microorganisms enclosed in an extracellular matrix. Although this organization of cells exists naturally in healthy skin, it is also involved in the pathogenesis of multiple skin disorders, such as acne a...
Review
Skin therapy letter. 2024 Nov;29(6):6-9. DOI: 2024